Ph.D., Partner, Morrison & Foerster LLP
Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing strategic, effective portfolio counseling and management. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including personalized medicine, cancer, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular disease, metabolic disorders, and neurodegenerative diseases such as Alzheimer's Disease. Her practice also includes due diligence evaluation and counseling in the context of venture investment assessments, as well as in connection with public and private financing, spin-offs, partnerships, and mergers and acquisitions. Dr. Polizzi is recognized as one of the Top 25 IP managers in California for six years running.
Session: Personalized Medicine Patent Law Update
In this timely session, top intellectual property attorneys Catherine Polizzi and Michael Shuster provide an update on patent law pertaining to personalized medicine issues. First, they give a brief recap of 35 U.S.C. 101 case law developments followed by a review of the 2014 Interim Guidance on Patent Subject Matter Eligibility under 35, in view of U.S. Supreme Court decisions. They survey recent patent prosecution results from diagnostics companies such as Myriad, Genomic Health, Ariosa, Sequenom and Roche and recap major litigations involving those and other diagnostics players, highlighting practical implications of developing 101 case law. Attendees will gain insight into how to adapt a patent strategy in light of these new developments.